Effect of Trimebutine and Rifaximin on Breath Hydrogen and Methane by Glucose Breath Test in Patients With Functional Bloating: A Randomized Double-blind Clinical Trial

Background/AimsDrugs that stabilize intestinal motility may improve the efficacy of nonabsorbable antibiotics, such as rifaximin, against small intestinal bacterial overgrowth (SIBO).We compared the efficacy of rifaximin alone with that of its combination with trimebutine maleate against SIBO. MethodsWe performed a randomized double-blind placebo-controlled trial (https://cris.nih.go.kr, no.KCT0004836) that included patients with functional bloating, no constipation, and SIBO using the hydrogen (H 2 )-methane (CH 4 ) glucose breath test (GBT).Patients were randomized into 2 groups in a 1:1 ratio, namely rifaximin (1200 mg/day) + trimebutine maleate (600 mg/day) group and rifaximin + placebo group, for 2 weeks.Patients completed a symptom questionnaire and underwent a GBT at baseline and at 1 month after treatment withdrawal.The primary outcome was SIBO eradication.The secondary outcomes included changes in the concentrations of exhaled gases, symptoms, and presence of adverse events. ResultsThe complete eradication rate of SIBO was 35.9% (14/39) in the rifaximin group, and 34.1% (14/41) in the combined group with no significant differences.In both groups, no significant differences were observed in GBT profiles before and after the treatment, respectively.However total breath H 2 and CH 4 concentration were conspicuously decreased in the combined group after treatment.The combined group exhibited substantial relief of bloating.The adverse events were similar in the 2 groups. ConclusionWhile the combination therapy was not superior over rifaximin alone for SIBO eradication, it improves the symptom of bloating with numerically reducing the concentration of breath H 2 /CH 4 .(